Costs and Resource Use of Mild Persistent Asthma Patients Initiated on Controller Therapy

References

• National Asthma Education and Prevention Program. NHLBI. 1997, Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma
   Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. NHLBI. 2006
   Google Scholar
• Ducharme F M. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment. BMJ 2003; 326: 621–625
   PubMed Web of Science ®Google Scholar
• Ducharme F M, Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. 2004, Cochrane Database of Systemic Reviews 00075320
   Google Scholar
• Boushey H A, Sorkness C A, King T S, Sullivan S D, Fahy J V, Lazarus S C, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352: 1519–1528
   PubMed Web of Science ®Google Scholar
• The American Lung Association Asthma Clinical Research Centers. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356: 2027–2039
   PubMed Web of Science ®Google Scholar
• Kluijver J, Evertse C E, Schrumpf J A, van der Veen H, Zwinderman A H, Hiemstra P S, et al. Asymptomatic worsening of airway inflammation during low-dose allergen exposure in asthma. Am J Respir Crit Care Med 2002; 166: 294–300
   PubMed Web of Science ®Google Scholar
• Purucker M E, Rosebraugh C J, Zhou F, Meyer R J. Inhaled fluticasone propionate by Diskus in the treatment of asthma. Chest 2003; 124: 1584–1593
   PubMed Web of Science ®Google Scholar
• Thomas M, Cleland J, Price D. Database studies in asthma pharmacoeconomics. Expert Opin Pharmocother 2003; 4: 351–358
   PubMed Web of Science ®Google Scholar
• Colice G, Wu E Q, Birnbaum H, Daher M, Marynchenko M B, Varghese S. Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med 2006; 48: 794–802
   PubMed Web of Science ®Google Scholar
• Colice G, Wu E Q, Birnbaum H, Daher M, Marynchenko M B. Use of inhaled corticosteroids and health care costs in mild persistent asthma. J Asthma 2007; 44: 479–483
   PubMed Web of Science ®Google Scholar
• National Committee for Quality Assurance. Use of appropriate medications for people with asthma. Technical Specifications, Washington, DC. vol 2, HEDIS 2005
   Google Scholar
• Leidy N K, Paramore L C, Watrous M, Doyle J, Zeiger R S. Development of an algorithm for estimating asthma severity from an administrative cost database. Value Health 1999; 2: 394
   Google Scholar
• Charlson M E, Pompei P, Ales K L, MacKenzie C R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373–383
   PubMedGoogle Scholar
• Romano P S, Roos L L, Jollis J G. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46: 1075–1079
   PubMed Web of Science ®Google Scholar
• Wolfe J, Rooklin A, Grady J, Munk Z M, Stevens A, Prillaman B, Duke S, Harding S. Comparison of once-and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol. 2000; 105: 1153–1161
   PubMed Web of Science ®Google Scholar
• Nathan R A, Li J T, Finn A, Jones R, Payne J E, Wolford J P, Harding S M. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma. Chest 2000; 118: 296–302
   PubMed Web of Science ®Google Scholar
• ZuWallack R, Adelglass J, Clifford D P, Duke S P, Wire P D, Faris M, Harding S M. Long-term efficacy and safety of fluticasone propionate powder administered once or twice daily via inhaler to patients with moderate asthma. Chest 2000; 118: 303–312
   PubMed Web of Science ®Google Scholar
• O'Byrne P M, Barnes P J, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. Am J Respir Crit Care Med 2001; 164: 1392–1397
   PubMed Web of Science ®Google Scholar
• Morbidity and Mortality Weekly Report. Asthma prevalence and control characteristics by race/ethnicity—United States, 2002. Morbid Mortal Wkly Rep MMWR 2004; 53: 7
   Google Scholar
• Beasley R. The burden of asthma with specific reference to the United States. J Allergy Clin Immunol 2002; 109: S482–S489
   PubMed Web of Science ®Google Scholar
• Birnbaum H G, Berger W E, Greenberg P E, Holland M, Auerbach R, Atkins K M, et al. Direct and indirect costs of asthma to an employer. J Allergy Clin Immunol 2002; 109: 264–270
   PubMed Web of Science ®Google Scholar
• Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: 1322–1326
   PubMed Web of Science ®Google Scholar
• Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity. Eur Respir J 2002; 19: 61–67
   PubMed Web of Science ®Google Scholar
• Cisternas M G, Blanc P D, Yen I H, Katz P P, Earnest G, Eisner M D, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003; 111: 1212–1218
   PubMed Web of Science ®Google Scholar
• Sullivan S D, Buxton M, Andersson F, Lamm C J, Liljas B, Chen Y Z, et al. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2003; 12: 1229–1236
   Web of Science ®Google Scholar
• O'Byrne P, Cuddy L, Taylor D W, Birch S, Morris J, Syrotuik J. Efficacy and cost benefit of inhaled corticosteroids in patients considered to have mild asthma in primary care practice. Can Respir J 1996; 3: 169–175
   Google Scholar
• O'Connor R D, Parasuraman B, Roberts C, Leibman C. Inhaled corticosteroids vs leukotriene receptor antagonists. Ann Allergy Asthma Immunol 2006; 97: 236–243
   PubMed Web of Science ®Google Scholar
• Orsini L, Limpa-Amara S, Crown W H, Stanford R H, Kamal K. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 2004; 92: 523–529
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Nelson L M, Kulkarni A S, Pleasants R A, Whitmire J T, Schechter M S. Outcomes associated with initiation of different controller therapies in a Medicaid asthmatic population. J Asthma 2005; 42: 35–40
   PubMed Web of Science ®Google Scholar
• Friedman H S, Yawn B P. Resource utilization in asthma. Curr Med Res Opin 2007; 23: 427–434
   PubMed Web of Science ®Google Scholar
• Rand C, Bilderback A, Schiller K, Edelman J M, Hustad C M, Zeiger R S, et al. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol 2007; 119: 916–923
   PubMed Web of Science ®Google Scholar
• Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996; 98: 1051–1057
   PubMed Web of Science ®Google Scholar
• Schatz M, Zeiger R S, Vollmer W M, Mosen D, Apter A J, Stibolt T B, et al. Validation of a β-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006; 117: 995–1000
   PubMed Web of Science ®Google Scholar
• Schatz M, Zeiger R S, Vollmer W M, D Mosen, Mendoza G, Apter A J, et al. The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes. Chest 2006; 130: 43–50
   PubMed Web of Science ®Google Scholar
• Schatz M, Nakahiro R, Crawford W, Mendoza G, Mosen D, Stibolt T B. Asthma quality-of-care markers using administrative data. Chest 2005; 128: 1968–1973
   PubMed Web of Science ®Google Scholar
• Cabana M D, Slish K K, Nan B, Clark N M. Limits of the HEDIS criteria in determining asthma severity for children. Pediatrics 2004; 114: 1049–1055
   PubMed Web of Science ®Google Scholar
• Berger W E, Legorreta A P, Blaiss M S, Schneider E C, Luskin A T, Stempel D A, et al. The utility of the Health Plan Employer Data and Information Set (HEDIS) asthma measure to predict asthma-related outcomes. Ann Allergy Asthma Immunol 2004; 93: 538–545
   PubMed Web of Science ®Google Scholar
• Fuhlbrigge A L, Carey V J, Finkelstein J A, Lozano P, Inui T S, Weiss S T, et al. Validity of the HEDIS criteria to identify children with persistent asthma and sustained high utilization. Am J Manag Care 2005; 11: 325–330
   PubMed Web of Science ®Google Scholar
• Mosen D M, Macy E, Schatz M, Mendoza G, Stibolt T B, McGaw J, et al. How well do the HEDIS asthma inclusion criteria identify persistent asthma. Am J Manag Care 2005; 11: 650–654
   PubMed Web of Science ®Google Scholar